Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
BioSpace12d
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
The Motley Fool1mon
Is Eli Lilly Stock a Buy?
Eli Lilly has been riding the weight-loss drug wave ... which is technically approved for type-2 diabetes patients. Off-label use of GLP-1 drugs to lose weight has become rampant, helping drive ...
Eli Lilly Q4 miss brings buying opportunity, says JPMorgan
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...
Yahoo Finance11d
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Also Read: Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue ... Omvoh is also being studied in VIVID-2, an ongoing ...
PMLiVE12d
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease ...